Zobrazeno 1 - 10
of 38
pro vyhledávání: '"L, van Andel"'
Autor:
P, Aviles, R, Altares, L, van Andel, R, Lubomirov, S, Fudio, H, Rosing, F M, Márquez Del Pino, M M, Tibben, G, Benedit, L, Nan-Offeringa, X E Luepke, Estefan, A, Francesch, A, Zeaiter, C, Cuevas, J H M, Schellens, J H, Beijnen
Publikováno v:
Drug Metabolism and Disposition. 50:327-340
Lurbinectedin is a novel and potent selective inhibitor of active transcription of protein-coding genes, triggering apoptosis of cancerous cells. It has been approved for the treatment of patients with metastatic small-cell lung cancer with disease p
Autor:
L T, van der Heijden, A, Gebretensae, B, Thijssen, L, van Andel, A L, Nijstad, Y, Wang, H, Rosing, A D R, Huitema, J H, Beijnen
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 215:114772
A highly sensitive method was developed for the quantification of vinblastine, vincristine, vinorelbine, and its active metabolite 4-O-deacetylvinorelbine in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Deuterated iso
Autor:
L, van Andel, E A, Aalbersberg, M M, Geluk-Jonker, M P M, Stokkel, J H, Beijnen, J J M A, Hendrikx
Publikováno v:
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 1171
Lutetium-177 [
Autor:
Zhi-Yi Zhang, Matthijs M. Tibben, M. Sanghvi, V. Kansra, A. Gebretensae, Hilde Rosing, Jos H. Beijnen, L. van Andel, J. H. M. Schellens, L. Hughes
Publikováno v:
Cancer Chemotherapy and Pharmacology. 81:39-46
Niraparib (Zejula™) is a poly(ADP-ribose) polymerase inhibitor recently approved by the US Food and Drug Administration for the maintenance treatment of patients with recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary perit
Autor:
L, van Andel, H, Rosing, M M, Tibben, L, Lucas, R, Lubomirov, P, Avilés, A, Francesch, S, Fudio, A, Gebretensae, M J X, Hillebrand, J H M, Schellens, J H, Beijnen
Publikováno v:
Cancer chemotherapy and pharmacology. 82(3)
Plitidepsin absorption, distribution, metabolism and excretion characteristics were investigated in a mass balance study, in which six patients received a 3-h intravenous infusion containing 7 mgBlood samples were drawn and excreta were collected unt
Autor:
L, van Andel, H, Rosing, Z, Zhang, L, Hughes, V, Kansra, M, Sanghvi, M M, Tibben, A, Gebretensae, J H M, Schellens, J H, Beijnen
Publikováno v:
Cancer Chemotherapy and Pharmacology
Introduction Niraparib (Zejula™) is a poly(ADP-ribose) polymerase inhibitor recently approved by the US Food and Drug Administration for the maintenance treatment of patients with recurrent platinum-sensitive epithelial ovarian, fallopian tube, or
Autor:
L, van Andel, S, Fudio, H, Rosing, S, Munt, B, Miguel-Lillo, I, González, M M, Tibben, N, de Vries, A H M, de Vries Schultink, J H M, Schellens, J H, Beijnen
Publikováno v:
Investigational new drugs. 35(5)
Plitidepsin (Aplidin®) is a marine-derived anticancer compound currently investigated in phase III clinical trials. This article describes the distribution, metabolism and excretion of this novel agent and it mainly aims to identify the major routes
Autor:
S. Lu, S. Agarwal, Zhi-Yi Zhang, Matthijs M. Tibben, Hilde Rosing, J. H. Beijnen, L. Hughes, J. H. M. Schellens, L. van Andel, V. Kansra
Publikováno v:
Clinical Therapeutics. 39:e7-e8
Autor:
J. H. M. Schellens, Matthijs M. Tibben, Hilde Rosing, Michel J.X. Hillebrand, Rubin Lubomirov, Andrés Francesch, Pablo Aviles, Salvador Fudio, L. Lucas, Jos H. Beijnen, L. van Andel, A. Gebretensae
Publikováno v:
Cancer Chemotherapy and Pharmacology, 82(3), 441. Springer Verlag
PURPOSE: Plitidepsin absorption, distribution, metabolism and excretion characteristics were investigated in a mass balance study, in which six patients received a 3-h intravenous infusion containing 7 mg 14C-plitidepsin with a maximum radioactivity
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.